Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 93 3-Year EBITDA Growth Rate is 8.90% as of Mar. 2026, which is 41% below its 10-year median of 15.00. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 50.06% on this metric.
During the past 12 months, Beximco Pharmaceuticals's average EBITDA Per Share Growth Rate was 21.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 14.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Beximco Pharmaceuticals was 28.70% per year. The lowest was -9.00% per year. And the median was 15.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Beximco Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
BXMPY vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.90% mean?
Beximco Pharmaceuticals (BXMPY) has a 3-Year EBITDA Growth Rate of 8.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Beximco Pharmaceuticals and its competitors. This is 41% below median its historical median of 15.00. According to the industry distribution chart, Beximco Pharmaceuticals ranks #404 out of 809 companies in the Drug Manufacturers industry, placing it in the top 49.9%.
Is Beximco Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Beximco Pharmaceuticals' current 3-Year EBITDA Growth Rate of 8.90% is 41% below median its 10-year median of 15.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Beximco Pharmaceuticals' value of 8.90% is 0% at this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #404 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #404 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Beximco Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Beximco Pharmaceuticals' value of 8.90% is 0% at this benchmark. While the company's 10-year median is 15.00 vs. the industry median of 8.90, Beximco Pharmaceuticals has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current 3-Year EBITDA Growth Rate of 8.90% is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current 3-Year EBITDA Growth Rate is 8.90%, which is 41% below median its own 10-year median of 15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current 3-Year EBITDA Growth Rate of 8.90%. The current 3-Year EBITDA Growth Rate is 8.90%, which is 41% below median its 10-year median of 15.00 and 0% at the Drug Manufacturers industry median of 8.90. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current 3-Year EBITDA Growth Rate is 8.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
